权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

In vivo inactivation of latent HSV by endonuclease-mediated mutagenesis

通过核酸内切酶介导的诱变体内潜伏 HSV 灭活

基本信息

批准号：
9199202
负责人：
KEITH R JEROME
金额：
$ 22万
依托单位：
FRED HUTCHINSON CANCER RESEARCH CENTER
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-01-01 至 2018-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9199202
关键词：
Acute Adverse effects Afferent Neurons Animals Antiviral Therapy Biology Cell Death Cells Chronic Cleaved cell Clinic Clinical DNA DNA Sequence Data Dependovirus Development Disease Doxycycline Enzymes Genes Genome Goals HIV Hepatitis B Herpes Simplex Infections Herpesviridae Infections Herpesvirus Type 3 Homing Human Papillomavirus Immunohistochemistry Individual Induced Mutation Infection Infiltration Inflammatory Inflammatory Response Injection of therapeutic agent Laboratories Latent Virus Latent virus infection phase Measures Mediating Methods Modeling Modification Morbidity - disease rate Mus Mutagenesis Mutate Mutation Neurons Pathway interactions Phase Positioning Attribute Primary Infection Production Recurrence Recurrent disease Safety Sampling Simplexvirus Site Site-Directed Mutagenesis Source Structure of trigeminal ganglion Technology Testing Tetracyclines Therapeutic Time Toxic effect Vaccines Vibrissae Viral Viral Genes Viral Genome Viral load measurement Viral reservoir Virus Virus Diseases Virus Latency Virus Replication Work base clinically relevant curative treatments digital endonuclease experience in vivo innovation knowledge base latent infection mouse genome mouse model next generation sequencing novel therapeutic intervention pre-clinical promoter public health relevance reactivation from latency research clinical testing spinal nerve posterior root tool transgene expression transmission process vector viral DNA virology virus pathogenesis

项目摘要

DESCRIPTION (provided by applicant): Herpes simplex virus (HSV) infections remain a common, serious problem associated with significant morbidity. After primary infection HSV establishes latency, which is not eliminated by current antiviral therapy, and latent virus is the source for viral reactivation and the recurrence of clinical disease. Despite much effort, a vaccine remains elusive. Therefore, there is a need for a new therapeutic approach that would cure latent HSV infection. Our hypothesis is that the emergence of designer rare-cutting endonucleases as powerful tools for directed genome modification offers the unique ability to selectively target, cleave, and disrupt essential viral DNA sequences within living cells. Here, we propose to use homing endonucleases (HEs) to disable HSV in latently infected neurons by targeted mutagenesis of essential viral genes, eliminating the source of viral reactivation and replication. The goal of this project is to optimize and evaluate our approach to eliminate latent HSV infection in vivo using a murine model of HSV latent infection. Moreover, our results will be directly applicable in efforts to cure varicella zoster virus, another alphaherpesvirus that like HSV establishes latency in sensory neurons. Furthermore, the data generated will be highly relevant to the development of a cure of other chronic or latent viral infections such as hepatitis B virus, HIV, or human papillomavirus. In SA1: Evaluate the efficacy in vivo of HE mutagenesis of HSV DNA in a mouse model of latent HSV infection, we will use our mouse model of latent HSV infection to test the ability of HEs to mutagenize HSV and disrupt its ability to reactivate. I SA2: Evaluate and optimize the safety in vivo of HE mutagenesis of HSV DNA in a mouse model of latent HSV infection, we will use our mouse model of latent HSV infection to evaluate and optimize the in vivo tolerability and safety of HE exposure. This project is expected to demonstrate the feasibility of our therapeutic approach directed towards the elimination of HSV pathogenesis in vivo, and to provide critical information for the development of a larger scale animal study necessary to bring this new therapeutic approach to the clinic.

描述(由申请人提供)：单纯疱疹病毒(HSV)感染仍然是一个常见的严重问题，与显著的发病率有关。HSV在初次感染后建立潜伏期，目前的抗病毒治疗无法消除这种潜伏期，而潜伏期病毒是病毒重新激活和临床疾病复发的来源。尽管付出了很多努力，疫苗仍然遥不可及。因此，需要一种新的治疗方法来治愈潜伏的HSV感染。我们的假设是，设计稀有切割内切酶作为定向基因组修改的强大工具的出现，提供了选择性地靶向、切割和破坏活细胞内的基本病毒DNA序列的独特能力。在这里，我们建议使用归巢核酸内切酶(HES)通过定向突变基本病毒基因来禁用潜伏感染神经元中的HSV，消除病毒重新激活和复制的来源。这个项目的目标是优化和评估我们的方法，以消除体内潜伏的HSV感染，使用HSV潜伏感染的小鼠模型。此外，我们的结果将直接适用于治愈水痘带状疱疹病毒的努力，水痘带状疱疹病毒是另一种与单纯疱疹病毒一样在感觉神经元中建立潜伏期的甲型疱疹病毒。此外，产生的数据将与其他慢性或潜伏性病毒感染(如肝炎)的治愈方法的开发高度相关 B病毒、艾滋病毒或人乳头瘤病毒。在SA1：在潜伏的HSV感染的小鼠模型中评估HSV DNA的HE突变的体内有效性，我们将使用我们的潜伏HSV感染的小鼠模型来测试HES诱变HSV的能力和破坏其重新激活的能力。I SA2：评估和优化HE诱变HSV DNA的体内安全性在潜伏HSV感染的小鼠模型中，我们将使用我们的小鼠潜伏HSV感染模型来评估和优化HE暴露的体内耐受性和安全性。该项目有望证明我们的治疗方法在体内消除HSV致病机制的可行性，并为将这一新的治疗方法引入临床所需的更大规模的动物研究的发展提供关键信息。